176 related articles for article (PubMed ID: 24923998)
1. Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening.
Bosgraaf RP; Verhoef VM; Massuger LF; Siebers AG; Bulten J; de Kuyper-de Ridder GM; Meijer CJ; Snijders PJ; Heideman DA; IntHout J; van Kemenade FJ; Melchers WJ; Bekkers RL
Int J Cancer; 2015 Feb; 136(3):646-55. PubMed ID: 24923998
[TBL] [Abstract][Full Text] [Related]
2. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program.
Gök M; van Kemenade FJ; Heideman DA; Berkhof J; Rozendaal L; Spruyt JW; Beliën JA; Babovic M; Snijders PJ; Meijer CJ
Int J Cancer; 2012 Mar; 130(5):1128-35. PubMed ID: 21484793
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs.
Bais AG; van Kemenade FJ; Berkhof J; Verheijen RH; Snijders PJ; Voorhorst F; Babović M; van Ballegooijen M; Helmerhorst TJ; Meijer CJ
Int J Cancer; 2007 Apr; 120(7):1505-10. PubMed ID: 17205514
[TBL] [Abstract][Full Text] [Related]
4. Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: Characteristics of the responders.
Gök M; Heideman DA; van Kemenade FJ; de Vries AL; Berkhof J; Rozendaal L; Beliën JA; Overbeek L; Babović M; Snijders PJ; Meijer CJ
Eur J Cancer; 2012 Aug; 48(12):1799-808. PubMed ID: 22172570
[TBL] [Abstract][Full Text] [Related]
5. HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.
Leeman A; Del Pino M; Molijn A; Rodriguez A; Torné A; de Koning M; Ordi J; van Kemenade F; Jenkins D; Quint W
BJOG; 2017 Aug; 124(9):1356-1363. PubMed ID: 28391609
[TBL] [Abstract][Full Text] [Related]
6. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
7. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
[TBL] [Abstract][Full Text] [Related]
9. Clinical Performance of hrHPV Primary Screening Using Vaginal versus Cervical Samples to Detect High-grade Intraepithelial Lesions.
King J; Flores YN; Meneses-León J; Hernández-Salazar S; Robles-Rivera K; Rivera-Paredez B; León-Maldonado L; Hernández-López R; Torres-Ibarra L; Lazcano-Ponce E; Salmerón J
Cancer Prev Res (Phila); 2023 Dec; 16(12):681-687. PubMed ID: 37788346
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
11. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
13. Colposcopy referral rate can be reduced by high-risk human papillomavirus triage in the management of recurrent atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology in Finland.
Jakobsson M; Tarkkanen J; Auvinen E; Häkkinen R; Laurila P; Tapper AM
Int J STD AIDS; 2012 Jul; 23(7):485-9. PubMed ID: 22844002
[TBL] [Abstract][Full Text] [Related]
14. Identification of a methylation panel as an alternative triage to detect CIN3+ in hrHPV-positive self-samples from the population-based cervical cancer screening programme.
de Waard J; Bhattacharya A; de Boer MT; van Hemel BM; Esajas MD; Vermeulen KM; de Bock GH; Schuuring E; Wisman GBA
Clin Epigenetics; 2023 Jun; 15(1):103. PubMed ID: 37322534
[TBL] [Abstract][Full Text] [Related]
15. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study.
Gök M; Heideman DA; van Kemenade FJ; Berkhof J; Rozendaal L; Spruyt JW; Voorhorst F; Beliën JA; Babovic M; Snijders PJ; Meijer CJ
BMJ; 2010 Mar; 340():c1040. PubMed ID: 20223872
[TBL] [Abstract][Full Text] [Related]
16. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial.
Verhoef VM; Bosgraaf RP; van Kemenade FJ; Rozendaal L; Heideman DA; Hesselink AT; Bekkers RL; Steenbergen RD; Massuger LF; Melchers WJ; Bulten J; Overbeek LI; Berkhof J; Snijders PJ; Meijer CJ
Lancet Oncol; 2014 Mar; 15(3):315-22. PubMed ID: 24529697
[TBL] [Abstract][Full Text] [Related]
17. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
[TBL] [Abstract][Full Text] [Related]
18. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
19. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
